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ABSTRACT
Biologic drugs offer major advancements over small-molecule drugs
when it comes to treating serious diseases. Biosimilars, which mimic
innovative biologic drugs, have the potential to further revolutionize
the practice of medicine. States now have decades of experience regu-
lating the substitution of generic, small-molecule drugs for their brand-
name equivalents. But the complexities of biologic drugs and biosimi-
lars force states to confront novel scientific and legal issues. Many
states have begun tackling those issues by passing laws that regulate
when pharmacists may substitute biosimilars for their corresponding
biologic drugs. Other states have yet to do so.  This Note surveys five
provisions common throughout current legislation: interchangeability,
indications to “Dispense as Written,” physician communication, pa-
tient notification, and recordkeeping. This Note goes on to argue that
states without biosimilar substitution laws should embrace all of these
provisions, except to the extent that notification provisions would allow
patients to opt out of biosimilar substitution without a legitimate medi-
cal reason. If states can appropriately balance promoting biosimilars
in the market while protecting patients’ safety, they can help more pa-
tients receive effective treatments while reducing spending on drugs.
INTRODUCTION
In 2015, healthcare spending in the United States increased at the fastest
rate since the economic downturn in 2008.1 The U.S. Department of Health
* J.D. Candidate, University of Michigan Law School; A.B. in Chemistry, Princeton
University. I would like to thank Professor Rebecca Eisenberg for her comments on an earlier
draft and her commitment to developing young scholars. Thanks also to Bethany Felder and
Caleb Kennedy for helpful feedback. This Note was last revised at the start of 2018, but this
area of the law is changing quickly. Any errors are mine alone.
1. Robert Pear, U.S. Health Spending in 2015 Averaged Nearly $10,000 Per Person,
N.Y. TIMES (Dec. 2, 2016), http://www.nytimes.com/2016/12/02/us/politics/us-health-care-
spending.html.
253
254 Michigan Telecommunications and Technology Law Review [Vol. 24:253
and Human Services calculated the total annual cost at $3.2 trillion—nearly
18% of the American economy.2 In particular, spending on prescription
drugs increased by 9% over the previous year to a total of nearly $325 bil-
lion.3 On average, the United States spends approximately twice as much on
healthcare as other developed countries.4 These numbers are alarming be-
cause increased healthcare costs potentially divert funds from other causes,
like Social Security, education, and infrastructure.
Over the years, physicians, politicians, and professors have suggested
ways to slow increasing healthcare costs. These commentators and policy-
makers aim to increase access to affordable medications (thereby lowering
total healthcare costs) while still ensuring patient safety. One effective
method for reducing the costs of small-molecule drugs is substituting ge-
neric versions for their corresponding brand-name counterparts.5 In 2015
alone, generic, small-molecule drugs saved the U.S. healthcare system ap-
proximately $232 billion.6 Although physicians and patients may opt for ge-
neric drugs, substitutions largely occur because states have enacted laws
requiring or permitting pharmacists to make them.7 But not all state substitu-
tion laws have kept pace with recent advances in biotechnology.
It may be possible for the United States to decrease spending on health-
care by replacing brand-name biologic drugs with related biologics, known
as biosimilars.8 Congress created an abbreviated pathway for the U.S. Food
and Drug Administration (FDA) to approve biosimilars as part of the Patient
2. Id.
3. Id.
4. Ian Read, All Americans Must Benefit from the Golden Age of Medicine, FORBES
(Nov. 29, 2016, 8:00 AM), http://www.forbes.com/sites/sciencebiz/2016/11/29/all-americans-
must-benefit-from-the-golden-age-of-medicine/#19f979452e0d. Read notes, however, that
spending on drugs in the United States more closely matches spending on drugs in other devel-
oped nations.
5. Small-molecule drugs are the drugs with which nearly everyone is familiar, as they
comprise over 90% of available drugs. See Small and Large Molecules, BAYER, http://
pharma.bayer.com/en/innovation-partnering/technologies-and-trends/small-and-large-mole-
cules/ (last visited Jan. 11, 2018). Small-molecule drugs “are synthesized in the classic way:
by chemical reactions between different organic and/or inorganic compounds.” Id. The para-
digmatic example is aspirin, which is easily formulated as a tablet. Id.
6. ASS’N FOR ACCESSIBLE MEDS., Generic Drug Access & Savings in the U.S. 39
(2017), https://www.accessiblemeds.org/sites/default/files/2017-07/2017-AAM-Access-Sav
ings-Report-2017-web2.pdf. But see Abigail Fagan, Generic Drugs Offer $73 Billion Savings,
SCIENCELINE (Nov. 14, 2016), http://scienceline.org/2016/11/generic-drugs-offer-73-billion-
savings/ (noting that the U.S. healthcare system could save an additional $73 billion on other
brand-to-generic substitutions); Melody Petersen, Drug Costs Skyrocket for Many Older Amer-
icans, Despite Medicare Coverage, L.A. TIMES (Nov. 23, 2016, 11:10 AM), http://www.la
times.com/business/la-fi-medicare-drug-costs-20161123-story.html (noting that costs for some
generic drugs continue to increase).
7. See infra Part I.
8. Andrew Pollack, Biotech Firms, Billions at Risk, Lobby States to Limit Generics,
N.Y. TIMES (Jan. 28, 2013), http://www.nytimes.com/2013/01/29/business/battle-in-states-on-
generic-copies-of-biotech-drugs.html.
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Protection and Affordable Care Act (ACA).9 The FDA must approve bi-
osimilars before they enter the market, but states retain the authority to de-
termine when and how pharmacists substitute biosimilars for their
corresponding brand-name biologic drugs (also known as “reference prod-
ucts”).10 Although thirty-six states have already enacted laws governing how
pharmacists may substitute biosimilars for prescribed biologic drugs, the re-
maining states have yet to do so.11 Plus, all fifty states could still amend their
laws before the first interchangeable biosimilar hits the market, i.e., when
biosimilar substitutions are likely to become more common.12
This Note argues that current legislation for biosimilar substitution pro-
vides a good model for states that have not yet passed such legislation. Part I
reviews state laws regulating the substitution of generic, small-molecule
drugs for brand-name drugs. Part II provides some background information
on biologic drugs and biosimilars. Part III considers five provisions that
often appear in existing state legislation on biosimilar substitution: inter-
changeability, indications to “Dispense as Written,” physician communica-
tion, patient notification, and recordkeeping. Part III goes on to argue that
states should include all of these provisions in their biosimilar substitution
laws, except that patient-notification provisions should not permit patients to
opt out unless they have a legitimate medical reason.
I. STATE LAWS FOR GENERIC SUBSTITUTION
Before turning to how states should regulate the substitution of biosimi-
lars for biologic drugs, it may be helpful to examine first how states regulate
the substitution of generic, small-molecule drugs for brand-name drugs.13
After all, the easiest way for a state to regulate biosimilar substitution would
be to copy as many of its provisions about generic drugs as possible. But
examining these laws for generic drug substitution might also reveal areas
where biosimilar substitution must necessarily differ.
Although substitution laws for generic drugs are well-established across
the entire United States, states handle these laws in different ways. This Part
reviews state laws governing the substitution of generic drugs for their
brand-name equivalents. It surveys several provisions common among state
laws and explains how those laws differ across jurisdictions.
9. See infra Part II.
10. See infra Part III.
11. Richard Cauchi, State Laws and Legislation Related to Biologic Medications and
Substitution of Biosimilars, NAT’L CONFERENCE OF STATE LEGISLATURES (Dec. 1, 2017), http:/
/www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-
substitution-of-biosimilars.aspx.
12. For an explanation of what makes a biosimilar “interchangeable,” see infra text
accompanying notes 66–70.
13. Readers who understand the intricacies of generic drug substitution but are not as
familiar with biologic drugs should feel free to skip ahead to Part II.
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All fifty states have enacted laws that regulate how pharmacists substi-
tute generic, small-molecule drugs for brand-name drugs.14 State laws differ,
however, on whether substitution is mandatory or merely permissive.15 Cur-
rently, fourteen states require pharmacists to substitute generic drugs for
brand-name drugs whenever generic drugs are available.16 The remaining
states mostly allow pharmacists to substitute generic drugs for brand-name
drugs at their discretion.17 Accordingly, one might expect that patients in
states with mandatory substitution laws receive generic drugs more fre-
quently than patients in states with only permissive substitution laws.18
Regardless of whether generic substitution is mandatory or permissive,
states use a few different approaches for determining whether substitution is
appropriate. Some states use positive or negative drug formularies.19 Positive
formularies identify which drugs pharmacists may (or must) substitute,
whereas negative formularies indicate which drugs pharmacists may (or
must) not substitute.20 Most states, however, do not use the formulary ap-
proach.21 In those states, pharmacists simply “must ensure that substitutions
are made within the requirements of the state law.”22
Whether or not they use formularies, some states rely on the FDA to
determine whether generic drugs are therapeutically equivalent to brand-
name drugs.23 The FDA publishes a list known as the “Orange Book,” which
identifies generic drugs that it has deemed “therapeutically equivalent to
other pharmaceutically equivalent products.”24 According to the FDA,
“products classified as therapeutically equivalent can be substituted with the
14. NAT’L ASS’N OF BDS. OF PHARMACY, SURVEY OF PHARMACY LAW 71–74 (2017)
[hereinafter SURVEY OF PHARMACY LAW].
15. Id. at 71.
16. The jurisdictions with mandatory substitution laws comprise a geographically and
politically diverse group: Florida, Kansas, Kentucky, Massachusetts, Minnesota, Mississippi,
Nevada, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Washington, and
West Virginia. See id.
17. Id.
18. Insurers might complicate this picture by deciding to cap reimbursements at certain
rates or using formularies to encourage filling prescriptions with generic drugs. See Charles
Ornstein & Katie Thomas, Prescription Drugs May Cost More with Insurance than Without It,
N.Y. TIMES (Dec. 9, 2017), https://www.nytimes.com/2017/12/09/health/drug-prices-generics-
insurance.html (noting that insurers make some drugs more expensive than they would other-
wise be). These concerns, while important, are generally beyond the scope of this Note.
19. SURVEY OF PHARMACY LAW, supra note 14, at 71.
20. Robert W. Piepho, Substitution at the Pharmacy Level, MEDSCAPE (Nov. 10, 2000),
http://www.medscape.org/viewarticle/416390_4.
21. SURVEY OF PHARMACY LAW, supra note 14, at 71.
22. Piepho, supra note 20.
23. SURVEY OF PHARMACY LAW, supra note 14, at 71, 73.
24. Orange Book Preface, U.S. FOOD & DRUG ADMIN. § 1.7 (June 10, 2016), http://
www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm. The Orange Book also
includes information on patents and regulatory exclusivity for small-molecule drugs. Id. § 1.1.
Those limited monopolies are beyond the scope of this Note.
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full expectation that the substituted product will produce the same clinical
effect and safety profile as the prescribed product.”25 But despite the FDA’s
expertise regarding therapeutic equivalence, the ultimate authority to regu-
late substitution rests with the state.26
States have devised a range of ways in which physicians may indicate
that generic drugs should not be substituted for prescribed, brand-name
drugs. Substitution would be inappropriate, for example, where a generic
drug contains an inactive ingredient that is not in the brand-name drug and
that the patient cannot tolerate.27 In states that have opted to use a two-line
prescription format, physicians sign on a line indicating that pharmacists
may substitute generic drugs for brand-name products.28 In states without
two-line prescription formats, physicians typically must write a phrase like
“Brand Medically Necessary,” “Dispense as Written,” or “Do Not Substi-
tute” on prescriptions to prevent generic substitutions.
Under all of these systems, some physicians instinctively require that
pharmacists dispense brand-name drugs even when generic drugs may be
appropriate.29 In response, some states have begun requiring physicians to
write down why prescriptions must be filled with brand-name drugs.30 After
passing such a law, Massachusetts saw a “dramatic” decrease of $150 mil-
lion in its Medicaid spending.31 Encouraging substitution whenever possible
allows states to realize the full benefits of generic drugs.
States differ on whether generic substitution requires patient aware-
ness.32 Most states require patient awareness in some form. Patient aware-
ness can be attained either through approval before pharmacists fill
prescriptions or through notification after pharmacists fill prescriptions.33
25. Id. § 1.2.
26. See United States v. Evers, 643 F.2d 1043 (5th Cir. 1981) (noting that federal law is
“not intended to regulate the practice of medicine”).
27. See Beth Levine, The Truth About Generic vs. Brand-Name Medications, HUF-
FINGTON POST (Feb. 22, 2015, 9:11 AM), https://www.huffingtonpost.com/2015/02/22/gener
ic-prescriptions_n_6730194.html (noting that a patient might have an allergic reaction to one
generic drug but not to another generic drug with the same active ingredient); see also Tina
Zerilli et al., To Substitute or Not to Substitute: That Is the Question, PHARMACY TIMES (Mar.
14, 2011), http://www.pharmacytimes.com/publications/issue/2011/march2011/genericfeature-
0311 (listing some generic drugs for which bioequivalence has been disputed).
28. SURVEY OF PHARMACY LAW, supra note 14, at 71, 73.
29. Ranit Mishori, Some Doctors Insist on Brand-Name Drugs Even When Cheaper
Generics Are Available, WASH. POST (July 11, 2011), http://www.washingtonpost.com/na
tional/some-doctors-insist-on-brand-name-drugs-even-when-cheaper-generics-are-available/
2011/06/13/gIQAmC0L9H_story.html?tid=a_inl (noting $7.7 billion in excess healthcare costs
per year).
30. Id. (“While some states require pharmacists to offer generic equivalents unless a
doctor specifies ‘Dispense as Written,’ a few jurisdictions are moving to limit the DAW
override.”).
31. Id.
32. SURVEY OF PHARMACY LAW, supra note 14, at 71.
33. Id. at 71 n.**.
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For example, Colorado requires that patients be notified both orally and in
writing.34 But there are still sixteen states where patient awareness is not
necessarily required.35 The end result is that not all patients who take generic
drugs will know that they are taking generics.
Some state generic substitution laws are more cost-conscious than
others. Because the major goal of generic substitution is to reduce healthcare
costs, most states require that dispensed generics be cheaper, or at least no
more expensive than, the prescribed brand-name drugs.36 Approximately a
dozen states even require that full cost savings must be passed on to pa-
tients.37 But the remaining states do not have any provisions discussing cost
savings.38
New York’s law on generic substitution illustrates some of the typical
provisions in this kind of legislation. Under New York’s generic substitution
law, prescribers must write “d a w” for “dispense as written” in a box on a
prescription pad to mandate that pharmacists fill prescriptions with brand-
name drugs.39 Otherwise, “the prescriber’s signature . . . shall designate ap-
proval of substitution” with generic drugs.40 Substitution is not required,
however, if pharmacists offer the brand-name drugs at the same prices as
generic drugs.41 In emergency situations, brand-name drugs may be dis-
pensed at their normal prices if generic drugs are not available.42 Finally,
prescribers must tell the patient whether brand-name or generic drugs have
been prescribed.43
Generic substitution laws remain robust across the United States.44 But
one practical implication of having states with different generic substitution
laws is that patients with the same prescriptions may end up taking different
brand-name or generic drugs, i.e., different formulations of the same active
ingredient. Plus, patients with the same prescriptions in different states may
have significantly different interactions with their pharmacists. As states
adapt their laws to account for biologic drugs, one might wonder whether
biosimilar substitution laws should diverge more or less from one another
than generic substitution laws.
34. Id. at 71, 74.




39. N.Y. EDUC. LAW § 6810(6)(a) (McKinney 2016).
40. Id.
41. Id.
42. An emergency situation is defined as a situation involving “any condition requiring
alleviation of severe pain or which threatens to cause disability or take life if not promptly
treated.” Id.
43. EDUC. § 6810(6)(b).
44. See SURVEY OF PHARMACY LAW, supra note 14, at 71–72 (comparing provisions
across all fifty states, D.C., Guam, and Puerto Rico).
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II. BIOLOGIC DRUGS & BIOSIMILARS
With systems for generic substitution in place, states have long accepted
generic drugs as familiar options within the healthcare system. But advances
in modern medicine have revolutionized the drugs that some patients now
receive. Biologic drugs and biosimilars differ from brand-name, small-mole-
cule drugs and generic drugs in significant ways. Crucially, biosimilars are
not merely generic biologic drugs. State laws for biosimilar substitution
must account for the differences between generic drugs and biosimilars. This
Part provides some necessary background information on biologic drugs and
biosimilars. It also explains how the federal government regulates approval
of biosimilars.
Biologic drugs differ from small-molecule drugs in important ways.
Whereas chemists synthesize small-molecule drugs using conventional labo-
ratory techniques,45 scientists must generate “protein-based” biologics “us-
ing DNA technology.”46 In other words, “a biologic comes from a living
organism” rather than “a set recipe” of chemicals.47 The resulting biologic
drugs are “complex macromolecular entities comprised of sugars, proteins,
or nucleic acids” in which the three-dimensional configuration is especially
important.48 Because of their complexity, biologic drugs are many times
more expensive than small-molecule drugs.49 But, despite their cost, biologic
drugs have proven particularly helpful for combatting serious diseases and
conditions that significantly lower patients’ quality of life, like cancer, ar-
thritis, and autoimmune disorders.50
Given the success of biologic drugs, competing manufacturers have
grown increasingly interested in bringing follow-on products, called “bi-
osimilars,” to market. These copycat biologics “are similar, but not identical,
to the biologics for which they will be substituted.”51 Under current limita-
tions of science, similarly designed biological products may have slightly
45. See supra note 5.
46. Stacey L. Worthy & John F. Kozak, Follow-On Biologics: Protecting Consumers
Through the State Pharmacy Law in Light of FDA Actions, 17 QUINNIPIAC HEALTH L.J. 207,
207–08 (2014).
47. Lindsay Kelly, Biologics in the Practice of Law, 39 HARV. J.L. & PUB. POL’Y 21, 21
(2016); see also Jordan Paradise, The Legal and Regulatory Status of Biosimilars: How Prod-
uct Naming and State Substitution Laws May Impact the United States Healthcare System, 41
AM. J.L. & MED. 49, 63 (2015) (“Biological products are derived from living materials, in-
cluding viruses, therapeutic serums, toxins and antitoxins, vaccines, blood and blood products,
and cells, tissues, and gene therapy products.”).
48. Paradise, supra note 47, at 64; see also W. Nicholson Price II & Arti K. Rai, Manu-
facturing Barriers to Biologics Competition and Innovation, 101 IOWA L. REV. 1023, 1026
(2016) (“In terms of size and rough complexity, if an aspirin were a bicycle, a small biologic
would be a Toyota Prius, and a large biologic would be an F-16 fighter jet.”).
49. Paradise, supra note 47, at 51 (noting that, on average, biological drugs are “twenty-
two times the price of traditional drugs”).
50. See Kelly, supra note 47, at 21; Worthy & Kozak, supra note 46, at 208.
51. Kelly, supra note 47, at 23.
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different structures.52 Considering the parallels with small-molecule drugs, it
may be enticing to view biosimilars as generic biologic drugs. But because
biosimilars are not identical to their corresponding biologic drugs, also
known as “reference products,” viewing biosimilars merely as generic bio-
logic drugs is misguided.53
Under federal law, the FDA’s process for approving biologic drugs and
biosimilars differs from its process for approving small-molecule drugs and
their generics. The FDA approves new small-molecule drugs under proce-
dures outlined in the Food, Drug & Cosmetic Act (FDCA),54 and it approves
generics under amendments called the Drug Price Competition and Patent
Term Restoration Act (Hatch-Waxman Act).55 The FDCA and the Hatch-
Waxman Act do not, however, address biologic drugs and biosimilars. In-
stead, the FDA approves biologic drugs under the Public Health Service Act
(PHSA).56 Until Congress passed the ACA in 2010,57 the FDA did not have
a mechanism for approving biosimilars.58 As part of the ACA, Congress
passed the Biologics Price Competition and Innovation Act (BPCIA), which
amended the PHSA so that the FDA could grant licenses for new
biosimilars.59
The BPCIA sets out the requirements that a biosimilar Biologics Li-
cense Application (bBLA) must meet for FDA approval.60 Under the statute,
a bBLA must include:
(aa) analytical studies that demonstrate that the biological product
is highly similar to the reference product. . .;
(bb) animal studies (including the assessment of toxicity); and
(cc) a clinical study or studies . . . that are sufficient to demonstrate
safety, purity, and potency.61
52. Jason Kanter & Robin Feldman, Understanding and Incentivizing Biosimilars, 64
HASTINGS L.J. 57, 59 (2012).
53. See Kelly, supra note 47, at 21 (“[T]here can be no ‘generic’ biologic.”).
54. Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codified as amended in scattered sections
of 21 U.S.C.).
55. Pub. L. No. 98-417, 98 Stat. 1585 (1984) (codified as amended in scattered sections
of 21 U.S.C.).
56. Pub. L. No. 78-410, 58 Stat. 682 (1944) (codified as amended in scattered sections
of 42 U.S.C.).
57. Pub. L. No. 111-148, 124 Stat. 119 (2010) (codified as amended in scattered sec-
tions of 26 and 42 U.S.C.).
58. See Kelly, supra note 47, at 22.
59. Paradise, supra note 47, at 64–65.
60. See id. Although Paradise uses the “bBLA” terminology, the BPCIA generally re-
fers to “an application under subsection (k).” E.g., 42 U.S.C. § 262(i)(2) (2012). I also use the
term “bBLA” for simplicity.
61. 42 U.S.C. § 262(k)(2)(A)(i)(I).
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According to the bBLA, the biosimilar must work via the same mechanism
of action as the reference product,62 and the biosimilar’s proposed use must
be the same as one of the reference product’s uses.63 Additionally, “the route
of administration, the dosage form, and the strength” of the biosimilar must
match the reference product.64 The FDA publishes a list of all approved bi-
osimilars in the “Purple Book.”65
The FDA may deem biosimilars that are highly similar to their reference
products as “interchangeable.” The BPCIA defines an interchangeable bi-
osimilar as one that “may be substituted for the reference product without
the intervention of the health care provider who prescribed the reference
product.”66 For the FDA to deem a biosimilar interchangeable, the bBLA
must show that the drug “can be expected to produce the same clinical result
as the reference product in any given patient.”67 Additionally, when patients
are meant to take the same biologic drug more than once, patients must be
able to switch back and forth between an interchangeable biosimilar and the
reference product without any additional risk.68 In making its determinations
regarding interchangeability, the FDA uses a “totality of the evidence” ap-
proach that it will undoubtedly refine as it gains experience with these appli-
cations.69 It also publishes its interchangeability determinations in the Purple
Book.70
Biosimilars are starting to enter the market. In 2015, the FDA approved
its first biosimilar, which was approved in Europe in 2009.71 The drug, San-
doz’s Zarxio, is similar to Amgen’s Neupogen and is intended to prevent
62. 42 U.S.C. § 262(k)(2)(A)(i)(II).
63. 42 U.S.C. § 262(k)(2)(A)(i)(III).
64. 42 U.S.C. § 262(k)(2)(A)(i)(IV).
65. Purple Book: Lists of Licensed Biological Products with Reference Product Exclu-
sivity and Biosimilarity or Interchangeability Evaluations, U.S. FOOD & DRUG ADMIN. (Sept.
15, 2017) [hereinafter Purple Book], http://www.fda.gov/Drugs/DevelopmentApprovalPro
cess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicAppli
cations/Biosimilars/ucm411418.htm; see also LIST OF LICENSED BIOLOGICAL PRODUCTS WITH
(1) REFERENCE PRODUCT EXCLUSIVITY AND (2) BIOSIMILARITY OR INTERCHANGEABILITY EVAL-




66. 42 U.S.C. § 262(i)(3).
67. 42 U.S.C. § 262(k)(4)(A)(ii).
68. 42 U.S.C. § 262(k)(4)(B).
69. See Kanter & Feldman, supra note 52, at 60 (“[T]he FDA released several draft
guidances in February 2012. . .. They outline the FDA’s ‘totality of the evidence’ approach to
biosimilar approval. . ..”).
70. See LIST OF LICENSED BIOLOGICAL PRODUCTS, supra note 65.
71. Sabrina Tavernise & Andrew Pollack, F.D.A. Approves Zarxio, Its First Biosimilar
Drug, N.Y. TIMES (Mar. 6, 2015), http://www.nytimes.com/2015/03/07/health/fda-approves-
zarxio-first-biosimilar-drug.html.
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infections in those undergoing chemotherapy.72 Since Zarxio, the FDA has
approved a handful of other biosimilar applications.73 For example, the FDA
approved a biosimilar version of Johnson & Johnson’s Remicade in April
2016.74 So far, the FDA has not deemed any of the approved biosimilars as
interchangeable.75 Despite the slow start, “[t]hings now seem to be heating
up,” and drug manufacturers are currently sponsoring approximately sixty
clinical trials aimed at gaining approval for new biosimilars.76 As more and
more biosimilars enter the market, the need for states to pass biosimilar sub-
stitution laws continues to grow.77
III. STATE BIOSIMILAR SUBSTITUTION LAWS
With the advent of biosimilars, states must reconsider how substitution
laws work for significantly different classes of drugs.78 This Part examines
five features of biosimilar substitution legislation: interchangeability, indica-
tions to “Dispense as Written,” physician communication, patient notifica-
tion, and recordkeeping. This Part goes on to argue that states should
embrace these provisions, provided that they do not allow patients to opt out
of substitution without a legitimate medical reason. These recommendations
are most relevant for states that have yet to pass biosimilar substitution laws,
but even states that have already passed such laws could still amend them
before the FDA designates a biosimilar as interchangeable.
States began passing biosimilar substitution laws only a few years ago.
Eight states led the way in 2013 and 2014,79 and seventeen states followed
72. Id.
73. See LIST OF LICENSED BIOLOGICAL PRODUCTS, supra note 65, at 1–3 (indicating
seven total biosimilar approvals).
74. Andrew Pollack, Makers of Humira and Enbrel Using New Drug Patents to Delay
Generic Versions, N.Y. TIMES (July 15, 2016), http://www.nytimes.com/2016/07/16/business/
makers-of-humira-and-enbrel-using-new-drug-patents-to-delay-generic-versions.html.
75. See LIST OF LICENSED BIOLOGICAL PRODUCTS, supra note 65, at 1–3 (making no
indications for interchangeable biosimilars).
76. Pollack, supra note 74.
77. See Zachary Brennan, FDA: Interchangeable Biosimilar Approvals Expected Within
2 Years, REGULATORY AFFAIRS PROF’LS SOC’Y (June 26, 2017), https://www.raps.org/regula
tory-focus%E2%84%A2/news-articles/2017/6/fda-interchangeable-biosimilar-approvals-expec
ted-within-2-years (noting that the FDA expects interchangeable biosimilars to hit the market
soon).
78. For a broader view of how states might handle the relationship between generic
drug and biosimilar substitution laws, see generally Brian F. King, Emerging Market for Bi-
osimilars: State Legislation Should Reconcile Biosimilar Substitution Laws with Existing Laws
on Generic Substitution, 18 DEPAUL J. HEALTH CARE L. 31 (2016).
79. Cauchi, supra note 11. Like the group of states with mandatory generic substitution
laws instead of permissive substitution laws, see supra note 16, this cohort of leading states is
geographically and politically diverse: Delaware, Florida, Indiana, Massachusetts, North Da-
kota, Oregon, Utah, and Virginia. See Cauchi, supra note 11.
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their lead in 2015 and 2016.80 In 2017, an additional eleven states passed
biosimilar substitution laws.81 Legislatures in eight states proposed bills that
ultimately failed.82 Only six states have not yet considered biosimilar substi-
tution laws at all.83 The laws already on the books typically contain provi-
sions related to biosimilars’ interchangeability, the prescriber’s ability to
block substitution, communication between the pharmacist and the pre-
scriber, patient notification, and recordkeeping.84
Interested parties have lobbied the states to enact laws with provisions
that favor their respective sides.85 Manufacturers of innovator biologic drugs
have asked states to pass biosimilar substitution laws that would generally
restrict pharmacists.86 At the same time, biosimilar manufacturers have ar-
gued for fewer restrictions on pharmacists.87 Lobbying efforts continue as
both sides encourage state legislatures to adopt policies that would benefit
sales of their brand-name biologic drugs or biosimilars.88
A. Interchangeability
Not all states impose requirements for the interchangeability of biosimi-
lars.89 Some states with biosimilar substitution laws insist that biosimilars
meet the FDA’s requirements for interchangeability before they can be sub-
stituted for their reference products.90 For example, Missouri law states that
a “pharmacist filling prescription orders for drug products prescribed by
trade or brand name may select another drug product . . . of the same . . .
interchangeable biological product type, as . . . accepted by the Federal
80. Those states are Arizona, California, Colorado, Georgia, Hawaii, Idaho, Illinois,
Kentucky, Louisiana, Missouri, New Jersey, North Carolina, Pennsylvania, Rhode Island, Ten-
nessee, Texas, and Washington. Id.
81. These recent actors are Iowa, Kansas, Maryland, Minnesota, Montana, Nebraska,
Nevada, New Mexico, New York, Ohio, and South Carolina. Id.; see also Senate Bill S4788A,
N.Y. STATE SENATE, https://www.nysenate.gov/legislation/bills/2017/s4788/amendment/a (last
visited Jan. 11, 2018) (noting that the governor signed New York’s pending bill).
82. Those states are Alabama, Alaska, Arkansas, Connecticut, Michigan, Mississippi,
Oklahoma, and Vermont. Cauchi, supra note 11.
83. The following states have not yet acted: Maine, New Hampshire, South Dakota,
West Virginia, Wisconsin, and Wyoming. Id.
84. See id. (comparing state law provisions).
85. See Pollack, supra note 8 (characterizing Virginia’s law as influenced by these lob-
bying efforts).
86. Id. (discussing lobbying efforts by Amgen and Genentech, including giving copies
of proposed bills to state legislators).
87. See id. (“Generic drug companies and insurers are taking their own steps to oppose
or amend the state bills, which they characterize as pre-emptive moves to deter the use of
biosimilars. . ..”)
88. See id. (“The trench fighting at the state level is the latest phase in a battle over the
rules for adding competition to the biotechnology drug market. . ..”)
89. SURVEY OF PHARMACY LAW, supra note 14, at 72.
90. Id. at 72–74.
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Food and Drug Administration.”91 In the BPCIA, Congress specified criteria
for the FDA to consider when it decides whether biosimilars are inter-
changeable.92 In fact, the BPCIA specifically contemplates substitution by
defining an interchangeable biosimilar as one that “may be substituted for
the reference product without the intervention of the health care provider
who prescribed the reference product.”93
Moving forward, states should require pharmacists to rely on the FDA’s
determinations of interchangeability. Simply put, the FDA has unmatched
scientific expertise in the area of biologic drugs. Unlike generic drugs,
whose applications only require proof of bioequivalence, bBLAs require at
least one clinical trial.94 The FDA has tremendous experience evaluating
data from clinical trials, while states do not. Because biosimilars are new
and more complicated than generic, small-molecule drugs,95 states should
not attempt to make their own determinations of which ones may be substi-
tuted for their reference products. Years from now, once scientists better
understand biologic products, states might consider adopting a formulary ap-
proach for biosimilars.96 But in the meantime, states should defer to the FDA
to reach the best clinical results.
B. Prescriber Prohibitions on Substitution
State laws generally agree that prescribers should be able to block the
substitution of biosimilars for prescribed biologic drugs.97 Like the mecha-
nisms for blocking generic substitution,98 standard procedure is for a physi-
cian to check a box or to write a phrase like “Brand Medically Necessary”
on the face of the prescription. For example, Missouri law establishes a two-
line format for prescriptions where physicians sign on a line marked “Dis-
pense as Written” to block substitution of a biosimilar for its reference prod-
uct.99 This mechanism provides the physician with a great deal of control
over which medication her patient will receive.
States that have not yet passed biosimilar substitution laws should in-
clude a provision that allows physicians to block substitutions when medi-
cally necessary. As with all provisions in biosimilar substitution laws, this
provision stems from concerns for patients’ safety. It ensures that patients
91. MO. ANN. STAT. § 338.056(1) (West 2016) (emphasis added).
92. See supra Part II.
93. 42 U.S.C. § 262(i)(3) (2012).
94. 42 U.S.C. § 262(k)(2)(A)(i)(I)(cc)(2012).
95. See supra Part II.
96. See supra text accompanying notes 19–20.
97. See Paradise, supra note 47, at 77, 78 fig. 1 (discussing the first eight biosimilar
substitution laws).
98. See supra Part I.
99. MO. ANN. STAT. § 338.056(2) (West 2016). The entire statutory section, including
this opt-out provision, covers both generic drugs and interchangeable biological products.
§ 338.056.
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who may not tolerate biosimilars as well as reference products will not suf-
fer from avoidable side effects.100 Patients and physicians know patients’
medical histories best, and physicians should be able to prevent any in-
creased risks to patients.
But states that have not yet passed biosimilar substitution laws should
also include provisions requiring physicians to explain why reference prod-
ucts must be dispensed instead of biosimilars. Unfortunately, some physi-
cians instinctively indicate that prescriptions should be dispensed as written
even when brand-name products are not medically necessary.101 Almost one
half of doctors participating in a survey “acknowledged holding some nega-
tive perceptions about the quality of generic medications,” even despite a
lack of evidence that such drugs are inferior.102 Given Massachusetts’s suc-
cess in amending its generic substitution laws to require doctors to explain
why brand-name drug are medically necessary,103 states should adopt the
same policy for biosimilars. This provision would prevent doctors from re-
flexively writing prescriptions for reference products without thoughtfully
considering substitution. Where medically necessary, patients would still be
able to receive reference products, but this provision would help states maxi-
mize the benefits of biosimilar substitution.
C. Communication with Prescribers
There is a consensus among states that have already passed biosimilar
substitution laws that those laws should include provisions requiring phar-
macists to provide information about substitutions to prescribing physi-
cians.104 When states passed the first biosimilar substitution bills, legislatures
required pharmacists to notify prescribers of any substitution.105 Now, the
laws typically specify that the pharmacist must “communicate with” the
physician about the substitution.106 For example, Massachusetts law prefers
that pharmacists communicate with physicians by noting any biosimilar sub-
stitutions in patients’ “interoperable electronic health record[s].”107 Commu-
nication does not slow down pharmacy transactions in the same way that
100. See supra note 27 and accompanying text.
101. Mishori, supra note 29.
102. Id.
103. See supra notes 30–31 and accompanying text.
104. See Cauchi, supra note 11.
105. Id. (“In bills enacted in 2013-2014, the language usually required that the prescriber
‘must be notified’ of any allowable substitution made at a pharmacy.”).
106. Id. (“[T]he language commonly has been adjusted to say ‘communicate with,’ al-
lowing a notation in an electronic medical record (EMR), PBM records or [a] ‘pharmacy re-
cord that can be electronically accessible by the prescriber.’“).
107. MASS. GEN. LAWS ANN. ch. 112, § 12EE(d) (West 2016) (when a pharmacy is not
equipped with interoperable electronic health records, the statute directs pharmacists to com-
municate with physicians by other means).
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notification might, which allows patients to receive necessary medications
faster.108
The consensus on this provision is largely due to lobbying efforts by
both sides. Although interest groups for reference product and biosimilar
manufacturers disagree on many aspects of biosimilar regulation, they have
reached a compromise on communication. The Biotechnology Industry Or-
ganization (BIO) and the Generic Pharmaceutical Association (GPhA)
agreed to the following language for proposed statutes: “[W]ithin a reasona-
ble time following the dispensing of a biological product, the dispensing
pharmacist . . . shall communicate to the prescriber the specific product pro-
vided to the patient.”109 Like many statutes, language in the Massachusetts
statute largely mirrors this suggested wording.110
States would be wise to continue following this compromise. Generally,
reference product and biosimilar manufacturers are diametrically opposed on
substitution laws; biosimilar companies want substitution to be as easy as
possible, while reference product companies want to restrict substitution.111
Their agreement on this issue signals that both sides believe this information
is required to protect patient safety.112 Doctors must know precisely which
medications their patients have taken in order to report adverse events, and
they need that information if patients must later take similar drugs. This
requirement is not controversial because physicians are better trained than
patients to understand the differences between reference products and
biosimilars.
D. Notifications for Patients
States are divided over whether pharmacists must notify patients when
they substitute biosimilars for reference products.113 For example, Massa-
chusetts law requires pharmacists to notify patients after substitutions.114
Other states require pharmacists to alert patients before the substitutions oc-
108. See Cauchi, supra note 11 (“This would allow a physician to assess and compare the
patient experience, but not delay the transaction.”).
109. Paradise, supra note 47, at 80 (quoting Randi Hernandez, Industry Players Reach
Compromise on Biosimilar Substitution, BIOPHARM INT’L (Dec. 12, 2014), http://www.bio
pharminternational.com/industry-players-reach-compromise-biosimilar-substitution). Since
this agreement, GPhA changed its name to the Association for Accessible Medicines (AAM).
110. See § 12EE(d) (“Within a reasonable time following any such substitution, the dis-
pensing pharmacist. . . shall notify the prescribing practitioner of the substitution.”).
111. See Pollack, supra note 8.
112. This requirement could potentially generate valuable data, providing an ulterior mo-
tive for BIO and AAM. But it is not clear how useful or accessible such data would be, and
this possibility would not delegitimize their patient safety concerns.
113. Cauchi, supra note 11.
114. § 12EE(e) (“Following any such substitution, the dispensing pharmacist. . . shall
notify the patient. . . of the substitution. The notification shall be written and may be conveyed
by facsimile, electronic transmission, a notation in the patients record system shared with the
prescriber or another means consistent with prevailing pharmacy practice. . ..”).
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cur.115 Virginia law, for instance, requires that pharmacists inform patients
“prior to dispensing the interchangeable biosimilar[s],” presumably giving
patients opportunities to object.116 These provisions seem motivated by the
idea that patients have a right to complete information about their healthcare.
At the opposite extreme, a few states do not require pharmacists to no-
tify patients at all.117 North Carolina is part of this minority.118 Legislators
might justify omitting such a provision because most consumers do not un-
derstand the difference between biosimilars and reference products. Others
might reason that, despite the lack of a provision, pharmacists might volun-
tarily provide the information to patients anyway. Overall, patients in some
states may become familiar with biosimilars, whereas patients in other states
may remain clueless.
States should not require pharmacists to receive patient approvals before
dispensing biosimilars. Patients might instinctively refuse biosimilars with-
out understanding the underlying science. For example, some patients might
believe that biosimilars are not as safe or effective as their reference prod-
ucts.119 But if biosimilars must be deemed interchangeable by the FDA
before they can be substituted,120 patient concerns about safety and efficacy
would be unfounded. Also, patients might reject biosimilars simply because
they recognize reference products’ brands. Preventing substitution in those
cases would be wasteful. Biosimilar substitution has the potential to save the
healthcare system from significant, unnecessary costs.121 Requiring patient
approval for substitution, however, might prevent states from realizing the
full benefits of biosimilars.
States should, however, require that pharmacists provide patients with
information about the substituted products that they receive. This informa-
tion could be conveyed, for example, through the labels accompanying bi-
osimilars. Of course, patients might not read this information; they might
only care whether the medication works.122 But for those who do wish to
learn more, labels would be informative. To be most helpful, the language
on these labels should be in layman’s terms. This information would provide
a good starting point for patients who want to discuss continuing treatment
115. Cauchi, supra note 11.
116. VA. CODE ANN. § 54.1-3408.04 (2016).
117. See Cauchi, supra note 11.
118. See N.C. GEN. STAT. § 90-85.28 (2016) (making no mention of any patient notifica-
tion requirement).
119. See supra text accompanying note 102.
120. See supra Section III.A.
121. See supra note 8 and accompanying text.
122. Patients might also not read drug labels because they find the sheer amount of infor-
mation in those labels overwhelming. See Ind. Univ. Sch. of Med., Information Overload in
Drug Side Effect Labeling, SCIENCEDAILY (May 24, 2011), https://www.sciencedaily.com/re
leases/2011/05/110523171058.htm (noting that the average drug label contains 70 different
side effects).
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options with their doctors. Overall, states should encourage pharmacists to
provide patients with complete information about their treatment without
confusing those patients.
E. Recordkeeping
States mostly agree that pharmacists and physicians should keep records
on which biosimilars are substituted for which patients.123 Generally, states
require that pharmacies keep records for at least a couple of years.124 On one
end of the spectrum, Massachusetts only requires pharmacies to keep records
of biosimilar substitutions for one year.125 On the other end of the spectrum,
Missouri law requires that pharmacies retain records for at least five years.126
However, Idaho does not require retention of any pharmacy records on bi-
osimilar substitution.127 Idaho law only requires that the biosimilar’s “name
. . . and the manufacturer or the NDC number [are] documented in the pa-
tient medical record.”128 Variations in these provisions mean that physicians,
pharmacists, and patients in different states might have different access to
historical prescription information.
States should require pharmacies to keep records on biosimilar substitu-
tions for at least as long as they currently require pharmacies to keep records
on generic substitutions. Biosimilar substitution records should not be overly
burdensome to maintain because states already keep track of generic substi-
tutions.129 These records also have the potential to help medical researchers.
For example, records may provide a bank of useful data for institutions con-
ducting research on the successes and drawbacks of substituting biosimilars
for their reference products.130 Retaining records is administratively feasible,
and it could help states protect their residents’ health.
Ideally, states should require pharmacies to retain records for biosimilar
substitution even longer than records for generic substitution. Generic drugs
123. Cauchi, supra note 11.
124. See id.
125. MASS. GEN. LAWS ANN. ch. 112, § 12EE (West 2016) (“The dispensing pharma-
cist. . . shall retain a record of each substitution, for not less than 1 year from the date of the
last entry in the profile record, of an interchangeable biological product dispensed.” (emphasis
added)).
126. MO. ANN. STAT. § 338.100(1) (West 2016) (“Every. . . pharmacy shall cause to be
kept in a uniform fashion. . . a suitable book, file, or electronic record-keeping system in which
shall be preserved, for a period of not less than five years, the original or order of each drug or
biological product which has been compounded or dispensed at such pharmacy. . ..” (emphasis
added)).
127. See IDAHO ADMIN. CODE r. 27.01.01.130 (2016).
128. Id.
129. See, e.g., MO. ANN. STAT. § 338.100(1)(West 2016) (requiring pharmacies to keep
“a suitable book, file, or electronic record-keeping system. . . for a period of not less than five
years”).
130. Again, it is not entirely clear how easily data could be integrated into clinical stud-
ies. See supra note 112.
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have been studied extensively, but there are some open questions about bi-
osimilars. History has shown that drugs’ long-term side effects may not be-
come evident until they enter the market.131 Because biosimilars are more
complex molecules than generic drugs,132 states should monitor them closely
while encouraging their use. Maintaining accurate records is a small but nec-
essary step toward achieving that goal.
In sum, when it comes to biosimilar substitution laws, states should
adopt provisions on interchangeability, prescribers’ ability to prevent substi-
tution, communication with prescribers, notification of patients, and record-
keeping. Those provisions should be finely tuned to protect current patients’
safety while promoting future patients’ health.
CONCLUSION
The advent and approval of biosimilars presents the United States with
novel scientific and legal problems. In light of congressional action and
FDA regulation, some states have already passed laws to address biosimi-
lars. States that have not yet passed biosimilar substitution laws should look
to current state legislation for guidance. They should embrace provisions
regarding interchangeability, prescriber prohibitions on substitution, com-
munication with prescribers, and recordkeeping while rejecting overly bur-
densome provisions regarding patient pre-approval. States that have already
enacted biosimilar substitution laws may still learn from these lessons before
the FDA deems the first biosimilar as interchangeable. If states find the right
balance between protecting patients’ safety and promoting biosimilars in the
market, biosimilars have the potential to be revolutionary.
131. See, e.g., Alex Berenson et al., Despite Warnings, Drug Giant Took Long Path to
Vioxx Recall, N.Y. TIMES (Nov. 14, 2004), http://www.nytimes.com/2004/11/14/business/de-
spite-warnings-drug-giant-took-long-path-to-vioxx-recall.html (chronicling the discovery of
cardiovascular risks associated with the drug Vioxx).
132. See supra Part II.
